Tag Archives: (TMO)

Behind Every Breakthrough Drug Is A Massachusetts Phone Number

My buddy who runs business development at a mid-cap biotech called me last week with an interesting complaint. He’s trying to scale up manufacturing for their promising Phase III candidate, and every vendor he talks to has the same response: “Great, we’ll get you on the Thermo Fisher (TMO) waiting list.” That conversation made me […]

The Magic Word Isn’t Please

Three months ago, my neighbor ended up in the emergency room with chest pains. False alarm, thankfully, but what struck me was how quickly they ran a dozen different tests and had results back within hours. The attending physician mentioned their lab equipment had been recently upgraded to “some Danaher (DHR) system that’s basically magic.” […]

Everyone Saw The Punch, No One’s Watching The Recovery

Thermo Fisher Scientific (TMO) just took a hit, but don’t mistake that for a knockout. This is a seasoned player, bloodied perhaps, but still very much in the game. The fundamentals are bruised, not broken. And for those who can look past the surface damage, the setup is starting to look unusually compelling. The company […]